PharVision Advisers’s Tronox TROX Stock Holding History

PharVision Advisers’s Portfolio TROX Stock Details TROX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,616	Closed	-$113K	–	131
2026 Q1	$113K	Buy	+11,616	New	+$80.5K	1.15%	36

Other funds holding TROX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PharVision Advisers's TROX Position: Q2 2026 in Review

PharVision Advisers sold out of Tronox (TROX) in Q2 2026, closing a stake of 11,616 shares — an estimated $113K sold.

PharVision Advisers first reported a position in TROX in Q1 2026 and held it in 1 quarter. The position peaked at $113K in Q1 2026. 238 funds tracked by Wall St. Rank hold TROX as of Q2 2026.

PharVision Advisers reported no remaining Tronox position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 11,616 Tronox shares in Q2 2026, an estimated $113K.
PharVision Advisers first reported a position in Tronox in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Tronox position peaked at $113K in Q1 2026.
238 funds tracked by Wall St. Rank held Tronox as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.